Howard Berman, Coya Therapeutics CEO
Six-person ALS biotech wants to go public — but it’s also pivoting from earlier plans
With an S-1 filing with the SEC on Friday, regulatory T cell operation Coya Therapeutics foreshadowed its plans to get on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
